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Abstract
Purpose: To determine whether alternative high dose rate prostate brachytherapy catheter patterns can result in similar
or improved dose distributions while providing better access and reducing trauma.
Materials and Methods: Standard prostate cancer high dose rate brachytherapy uses a regular grid of parallel needle
positions to guide the catheter insertion. This geometry does not easily allow the physician to avoid piercing the critical
structures near the penile bulb nor does it provide position flexibility in the case of pubic arch interference. This study
used CT datasets with 3 mm slice spacing from ten previously-treated patients and digitized new catheters following three
hypothetical catheter patterns: conical, bi-conical, and fireworks. The conical patterns were used to accommodate a robotic
delivery using a single entry point. The bi-conical and fireworks patterns were specifically designed to avoid the critical
structures near the penile bulb. For each catheter distribution, a plan was optimized with the inverse planning algorithm,
IPSATM, and compared with the plan used for treatment. Irrelevant of catheter geometry, a plan must fulfill the RTOG-0321
dose criteria for target dose coverage (V Prostate100 > 90%) and organ-at-risk dose sparing (V
Bladder
75 < 1cc, V
Rectum
75 < 1cc,
V Urethra125 << 1cc).
Results: The three non-standard catheter patterns used 16 non-parallel, straight divergent catheters, with entry points in
the perineum. Thirty plans from ten patients with prostate sizes ranging from 26 to 89 cc were optimized. All non-standard
patterns fulfilled the RTOG criteria when the clinical plan did. In some cases, the dose distribution was improved by better
sparing the organs-at-risk.
Conclusion: Alternative catheter patterns can provide the physician with additional ways to treat patients previously
considered unsuited for brachytherapy treatment (pubic arch interference) and facilitate robotic guidance of catheter
insertion. In addition, alternative catheter patterns may decrease toxicity by avoidance of the critical structures near the
penile bulb while still fulfilling the RTOG criteria.
Keywords: HDR, Brachytherapy, Inverse planning, IPSATM, Novel catheter patterns.
1 Introduction
Excellent survival rates and local control have been reported
using prostate high dose rate (HDR) brachytherapy [1, 2, 3, 4].
The next challenge facing the field involves reducing trauma
and side effects, and removing the obstacles that prevent
patients from being qualified for brachytherapy treatment.
Trauma to the critical structures near the penile bulb (ure-
thra, nerves, vessels, and penile bulb) from the insertion of
the brachytherapy catheters may be a key component of the
former, while pubic arch interference contributes to the lat-
ter [5, 6]. It has been shown that radiation delivered to the
penile bulb can lead to erectile dysfunction [7, 8, 9]. This
may be secondary, though, to damage to the cavernous ar-
teries running along the side of the penile bulb where physi-
cal trauma has been shown to cause erectile dysfunction [10].
In light of these results, it is reasonable to hypothesize that
trauma from needle puncture to the critical structures near
the penile bulb (CSNB) may be deleterious to erectile func-
tion1. Both pubic arch interference and trauma to the CSNB
from needle puncture are direct consequences of the standard
setup used for the transperineal insertion of the brachyther-
apy catheters that allows for little deviation from a parallel
implantation geometry.
Since the advent of anatomy-based inverse planning early
in this decade, there has been discussion in the field about
whether the standard template-based brachytherapy proce-
dure is necessary or whether it is viable to use alternative ge-
ometries. For example, inverse planning has allowed for the
development of template-less implantation of HDR brachy-
therapy catheters [11], though in this case the implanted
catheters are roughly parallel, each with a different skin-
entry point in the perineum. The beginning of this decade
also evidenced pioneering work in understanding the feasibil-
1Where applicable, the CSNB is inclusive of the penile bulb.
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ity of alternative catheter patterns in the context of Prostate
Permanent-seed Implant brachytherapy (PPI). Van Gellekom
et al. were the first to introduce the concept of using a sin-
gle needle to implant PPI seeds [12]. This was inspired by
the desire to use a robot for seed placement and resulted in
a conical seed geometry. Fu et al. followed with work that
applied inverse planning techniques to a conical PPI implant
geometry [13, 14]; and Van den Bosch et al. modified our
IPSATM [15, 16, 17] code to perform dose coverage studies of
conical and bi-conical PPI seed geometries [18].
The work discussed here moves away from PPI and explores
the concept of alternative catheter patterns in the context of
HDR brachytherapy. We focus on determining the clinical fea-
sibility of alternative HDR brachytherapy catheter patterns.
To this end we do not modify the optimization code, IPSATM,
in any way. For the purpose of this paper, clinical feasibility
is defined in the physics-based terms of determining whether
clinically acceptable dose distributions can be generated from
non-standard catheter patterns.
Standard clinical HDR brachytherapy practice uses a me-
chanical template of a regular geometry to guide linear
catheters transperineally into the body in parallel with lit-
tle or no curvature. This setup nearly guarantees that the
catheters pierce the CSNB and has little flexibility to work
around a pubic arch that extends inferior of the prostate. We
relaxed the constraint on parallelism to determine the dosi-
metric quality achievable via HDR brachytherapy using non-
parallel catheter arrangements. The three geometries pre-
sented show that non-standard catheter patterns: (1) are able
to circumvent pubic arch interference; (2) are able to avoid
piercing the CSNB; and (3) accommodate a single-point-of-
entry robotic system.
2 Materials and Methods
2.1 Planning system and dataset
All catheter digitization and DVH generation was performed
on Nucletron’s clinical brachytherapy platform, PLATO.
The IPSATM inverse planning optimization engine available
through PLATO was used to generate the plans. CT datasets
from ten previously-treated patients were used and catheters
were digitized in three hypothetical patterns: conical, bi-
conical, and fireworks. Since 16 catheters were used for all
the actual treatments, we restricted the new catheter patterns
to no more or less than 16 catheters. Treatment plans were
generated with a prescription dose of 950 cGy per fraction.
2.2 Catheter patterns
The conical and bi-conical geometries were inspired by future
robotic delivery systems that may require a single point of
entry for the catheters [19, 20]. The bi-conical and fireworks
patterns were specifically designed to avoid the CSNB. The
contoured penile bulb was used to represent both the penile
bulb itself and the harder-to-image CSNB. The three patterns
examined in the study are shown in Figures 1 and 2. Along
with a conical catheter pattern, the 3D anatomy reconstruc-
tion is overlaid on a sagittal 2D image slice in Figure 3. For
this study, all catheters were digitized as straight needles with
no curvature.
2.2.1 Conical patterns
The conical catheter patterns examined in this study have
their apex situated in the first subcutaneous CT slice of the
patient image set. The effect of placing the apex one slice
extra in both the super- and subcutaneous directions was ex-
amined and found to be negligible.
To create the single-cone catheter pattern, the digitization
process proceeded using the actual implant digitization as a
guide. The base of every catheter was digitized in the per-
ineum, all at a single point. Next, all other digitized catheter
positions were removed, preserving only the most superior
digitized point for each catheter (i.e., the tip of the catheter).
The result is a conical pattern of straight catheters of various
lengths depending on the depth of the prostate and blad-
der. Unlike in [18], all catheters passed entirely through
the prostate and none needed to be terminated early due to
urethral interference. None of the newly digitized catheters
passed through the urethra, rectum, or bladder.
Digitization of the two-cone catheter patterns started with
the single-cone pattern described above. Maintaining the
catheter tip location, the bases of the catheters were separated
into two groups. Each group was collected at its respective
entry point, one on each side of the perineum to from two
cone-shaped patterns. Because one of the goals of this study
was to evaluate the ability to avoid puncture of the CSNB
while maintaining adequate dose coverage, the CSNB were
avoided for all catheters.
2.2.2 Fireworks catheter pattern
In this case the physician would insert four larger-than-
normal-gauge catheters into the perineum and past the
CSNB, creating a conduit for the standard source-bearing
catheters, which may be inserted without each having to each
pierce the skin. At the top of the conduit, the source-bearing
catheters diverge to access all parts of the prostate.
These patterns were again based on the catheter placement
used in the actual treatment. For this step, the tips of the
catheters were left stationary, but all other digitized loca-
tions were removed. The four larger-gauge catheters—one for
each quadrant of the prostate as viewed transversely—were
digitized from the perineum to the last slice with a contoured
CSNB. The treatment catheters were then split into four four-
catheter groups and connected to the guide catheters.
A fireworks-like pattern would allow for complete physical
avoidance of the CSNB while still maintaining a quality dose
distribution and was inspired by the fact that impotence is a
common side affect of brachytherapy not only because of the
radiation delivered to the penile bulb but also from the phys-
ical puncturing of the CSNB by the brachytherapy catheters.
2
3 Results
Table 1 shows the results from this study. The standard
criteria recommended by the RTOG-0321 protocol [21] are:
V Prostate100 > 90%, V
Bladder
75 < 1 cc, V
Rectum
75 < 1 cc, and
V Urethra125 << 1 cc. For each of the ten patients, the RTOG-
0321 criteria are presented. In our clinic, IPSATM consis-
tently allows us to obtain V Urethra125 = 0 cc, therefore we use
(and report here) the more-strict V Urethra120 . (Heretofore, when
the RTOG-0321 protocol is mentioned in the context of this
study we mean to reference V Urethra120 rather than V
Urethra
125 .)
We also include V Urethra150 , V
Prostate
150 , and the prostate homo-
geneity index, HI = V
Prostate
100 −V Prostate150
V Prostate100
since these are used in
our clinic to augment the RTOG-0321 criteria. The HI is de-
sired to be greater than 0.6. The plan used for the actual pa-
tient treatment is listed in the column marked “Original” and
was considered the control sample to which the non-parallel-
catheter plans can be compared. All three of the experimental
catheter configurations were able to satisfy the RTOG-0321
criteria when the clinically used plan did. Only two of the 30
plans had a HI less than 0.60 (0.59 in both cases).
The two cases in which the catheter patterns (both the ac-
tual implant and the experimental patterns) were not able
to fulfill the RTOG-0321 criteria were exceptional anatomi-
cal cases. Case 8 had a long thin superior extension of the
prostate posterior to the bladder that was hard to accom-
modate without a suboptimal dose delivered to the bladder.
The prostate size in Case 9 was large (89.0 cc) and would
have benefited from the use of more catheters. We did not
increase the catheter number in order to preserve this vari-
able as constant across all studies for this patient. Despite
the large contoured penile bulb in this case (and thus large
region of possible location for the CSNB), the CSNB-sparing
patterns were able to obtain a dose coverage of similar quality
to the actual treatment while still avoiding puncture of the
bulb/CSNB region2. Prostate size, however, is not necessar-
ily a limiting factor—Case 4 has clinically acceptable results
even with a prostate volume of 80.2 cc.
Box-and-whisker diagrams of the V Prostate100 , V
Prostate
150 , HI,
V Urethra120 , V
Rectum
75 , and V
Bladder
75 data from Table 1 are shown
in Figures 4 and 5. For each dosimetric variable, the distribu-
tion of values for each catheter pattern is shown. A standard
construction of rank-based box-and-whisker plots was used:
the box encompasses the inner two quartiles (the range of
which is the inner quartile range, IQR) with a hash at the
median value of the distribution; the whiskers end at the low-
est(highest) measured value within the box edge minus(plus)
1.5× IQR. If there is no value within this range the whisker
is not drawn (i.e. the whisker ends at the edge of the box).
It is clear from Figure 4 that the ability to deliver a clin-
ically acceptable dose to the prostate target is independent
2Note that our clinic uses 16 catheters for every HDR brachytherapy
plan. This is because our experience has been that the benefits of in-
creased radiological coverage are offset by the side effects which result
from normal tissue trauma when more than 16 catheters are physically
inserted into the body. It was our desire to to minimize the work flow
changes needed to implement this method. As such, we kept the number
of catheters the same as would be used in our actual clinical setting.
of the catheter pattern used. In addition, the distribution of
doses in Figure 5 shows that for the surrounding organs, there
is no clinically significant difference between the alternative
catheter patterns and the original, clinically-used plan.
The measured dosimetric variables are not expected to fol-
low a Gaussian distribution (or any other parametric distri-
bution). Therefore, the quantitative statistical significance of
our results was determined via a Friedman test. This non-
parametric rank test determines whether the results across
all tests (original, conical, bi-conical, and fireworks) are con-
sistent. Consistency is defined by evaluating whether the null
hypothesis, H0 (all treatments have identical results) is valid.
The alternative hypothesis is that at least one treatment is
different from at least one other treatment. The validation of
H0 is quantified by the test statistic, S,
S =
12
np(p+ 1)
 p∑
j=1
(R2j )
− 3n(p+ 1), (1)
where Rj is sum of the ranks for catheter pattern j, n is the
number of patients, and p is the number of catheter patterns
studied [22].
For this experiment, n = 10 and p = 4. The degrees of
freedom is given by p − 1. For n = 10, three degrees of
freedom, and a significance level of 5% (α = 0.05), the cutoff
value for the test statistic is S = 7.81. If H0 is true and this
experiment is run an infinite number of times, 95% of the
results will yield a value S ≤ 7.81 and 5% of the results will
yield a value of S > 7.81.
We obtain the following S values:
S(V Prostate100 ) = 2.19
S(HI) = 3.18
S(V Urethra120 ) = 3.63
S(V Rectum75 ) = 5.88
S(V Bladder75 ) = 2.97
Since all values are less than 7.81, we are at least 95% certain
that the differences we see are entirely due to random fluctu-
ations and therefore the null hypothesis is valid: There is no
statistically significant difference between any of the alterna-
tive plans and the original.
4 Discussion
There has been discussion in the literature about conical nee-
dle configurations [12, 13, 14, 18], but all are in the context
of PPI brachytherapy. The work presented in Reference [18],
for example, modified the IPSATM code to examine the po-
tential of conical catheter patterns. However, the work pre-
sented here addresses the viability of conical catheter patterns
in HDR brachytherapy and examines the feasibility of non-
standard catheter patterns using clinically-available software.
To reiterate the focus of this study, we have shown that
while standard HDR brachytherapy uses a regular-grid tem-
plate for catheter placement, that particular configuration is
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not necessary to achieve a clinically acceptable plan. Parallel-
catheter-based brachytherapy techniques were developed to
help ensure a uniform conformal dose distribution prior to
the advent of inverse planning and present-day imaging tech-
nology. However, catheter implant technology is moving past
the need for a fixed rectangular template. In fact, we have
been using a freehand TRUS-guided system that incorporates
non-parallel needles since 1997 [11]. The catheter implanta-
tion still results in mostly parallel catheters (though this is
not a requirement).
It should also be noted that robotic delivery devices that
will be coming to market in the near future [19, 20] have the
potential to provide placement on the order of millimeters.
In this context, the use of a template is no longer a neces-
sity; and, alternative catheter placement patterns should be
explored so that the best patterns can be exploited. For ex-
ample, because of their location on the lateral portions of the
prostate, a conical catheter pattern with its apex centrally
located could allow for easier avoidance of the neurovascular
bundles.
Data regarding long-term efficacy of HDR brachytherapy
are continuing to emerge. For patients who are suited for
HDR brachytherapy treatment, a number of studies have been
released in recent years. In 2004, William Beaumont Hospi-
tal reported biochemical control in 98% of patients at a fol-
lowup of 35 months [1]. In 2005, with a median followup of
7.25 years, the California Endocurietherapy Cancer Center
reported a general clinical control rate of 90% with a cause-
specific survival rate of 97% [2]. In 2005, UCSF reported
4-year overall and disease-free survival rates of 95% and 92%,
respectively, for patients treated with an HDR boost to ex-
ternal beam radiotherapy [3]. And in 2006, Osaka University
reported 3- and 5-year local control rates of 100% and 97% [4].
However, there is still much progress to be made in reducing
side effects of treatments and increasing the percentage of
patients for whom brachytherapy is an option. Moving away
from a template-based HDR brachytherapy procedure is a key
way to move forward. We have shown here that alternative
catheter patterns can result in clinically identical dose cover-
age and therefore equal survival rates. The main argument
here, however, is not that clinically acceptable HDR brachy-
therapy dose profiles can be achieved, but rather that, just as
for PPI procedures, it can be done while avoiding penetration
of the CSNB and/or avoiding pubic arch interference.
Note that while we explicitly avoided piercing the CSNB
in the bi-conical and fireworks catheter patterns, no attempt
was made to further reduce the dose to the CSNB. It has
been shown [17] that inverse planning can reduce the dose to
the penile bulb at little or no cost to the target coverage or
sparing of the other organs at risk. It may also be possible
to generate plans with these new catheter patterns using a
smaller number of catheters, thus possibly further reducing
trauma.
5 Conclusion
We have examined the feasibility of using alternative
HDR brachytherapy catheter patterns to produce clinically-
acceptable dose plans for prostate cancer treatment. Us-
ing ten previously-treated patient anatomical data and
three alternative catheter geometries—conical, bi-conical, and
fireworks—we have shown that it is possible to generate dose
plans that are clinically acceptable and at least as good as
the plan used in the actual patient treatment. We have
changed the optimization procedure as little as possible from
our clinic’s standard work flow in order to show that minimal
fine tuning is necessary and therefore implementation in the
clinic, in regards to dose planning, is trivial.
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Figure 1: A computer generated image of the catheter arrangements used in this study. All four images are for the same
patient. The bladder is in the upper right, the prostate (target volume) in the center and contains the urethra, and the
rectum on the bottom. The contoured region to the left of the prostate represents both the penile bulb and the CSNB. In
the original dose planning, it was contoured as a general region of avoidance. The catheters enter from the lower left of the
figure, which corresponds to the patient’s perineum. Upper left: The standard implant used in the actual patient treatment.
Note that the catheters pierce the contoured bulb/CSNB. Upper right: A hypothetical Fireworks distribution. The Fireworks
configuration of catheters allows for avoidance of the contoured bulb/CSNB. Lower left: The conical shape of the implant
allows for a single entry point for all catheters. The apex of the cone is located at the patient’s perineum; catheters spread
as they approach the prostate to cover the prostate while avoiding the urethra. Lower right: The bi-conical catheter pattern
can accommodate a single entry point, circumvent the contoured bulb/CSNB, and access parts of the target volume behind
the urethra inaccessible via the standard or conical approach.
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Figure 2: Cunha: Dosimetric equivalence of non-standard catheter patterns. Color figure available online. The
transverse view of the same images presented in Figure 1. Here the bladder is in the upper portion of the image, followed by
the contoured bulb/CSNB, the prostate, the urethra, and finally the rectum in the lower portion. The catheters enter from
the lower foreground (the patient’s perineum) and proceed into the page. Upper left : A standard implant used in the actual
patient treatment. Upper right : The same patient, but with a hypothetical Fireworks distribution. Lower left : A single-cone
catheter pattern. Lower right : A bi-conical catheter pattern.
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Figure 3: A sagittal view of one of the patients in our study that shows the conical pattern used. On the far right (in white)
is the balloon at the end of the Foley Catheter inside the bladder. The inferior slices of the bladder are contoured. To the
left of the bladder is the prostate surrounding the urethra. Below the prostate is the rectum and above it is the pubic arch.
To the left of the prostate is the contoured bulb/CSNB. The catheters enter from the perineum on the left of the image.
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Table 1: Dosimetric plan-evaluation criteria for the actual treatment plan (Original) and the three other plan geometries
examined in this study. All alternative catheter patterns satisfy the RTOG-0321 protocol criteria when the original plan did.
Note that in most cases, the alternative geometries are either as good or better than the clinical plan.
Case 1 (V=42.3cc) Original Cone Cone2 Firework Case 6 (V=33.3cc) Original Cone Cone2 Firework
Bladder V75 (cc) 1.42 0.29 0.91 1.31 Bladder V75 (cc) 0.45 0.66 0.82 0.30
Rectum V75 (cc) 0.52 0.59 0.99 0.82 Rectum V75 (cc) 0.76 0.65 0.81 0.63
Urethra V100 (cc) 0.97 0.85 1.02 0.95 Urethra V100 (cc) 0.95 0.96 0.85 0.94
Urethra V120 (cc) 0.30 0.03 0.80 0.46 Urethra V120 (cc) 0.18 0.10 0.03 0.10
Target V100 (%) 88.9 89.1 89.6 89.4 Target V100 (%) 90.7 93.6 91.5 90.3
Target V150 (%) 28.2 31.4 32.3 34.8 Target V150 (%) 28.6 27.7 34.8 29.7
Target HI 0.58 0.65 0.64 0.61 Target HI 0.69 0.70 0.62 0.67
Case 2 (V=44.5cc) Original Cone Cone2 Firework Case 7 (V=26.4cc) Original Cone Cone2 Firework
Bladder V75 (cc) 0.98 0.81 0.72 0.66 Bladder V75 (cc) 0.77 0.76 0.84 0.65
Rectum V75 (cc) 0.77 0.21 0.16 0.20 Rectum V75 (cc) 0.28 0.33 0.30 0.20
Urethra V100 (cc) 1.37 1.42 1.37 1.39 Urethra V100 (cc) 1.54 1.48 1.57 1.54
Urethra V120 (cc) 0.25 0.41 0.45 0.29 Urethra V120 (cc) 0.41 0.53 0.04 0.16
Target V100 (%) 97.0 94.6 94.6 94.6 Target V100 (%) 91.6 93.5 94.2 92.4
Target V150 (%) 0.40 30.5 30.8 32.3 Target V150 (%) 36.1 36.3 31.1 34.6
Target HI 0.58 0.68 0.67 0.66 Target HI 0.61 0.61 0.67 0.63
Case 3 (V=49.4cc) Original Cone Cone2 Firework Case 8 (V=44.5cc) Original Cone Cone2 Firework
Bladder V75 (cc) 0.94 0.90 0.81 0.84 Bladder V75 (cc) 2.35 2.39 2.24 2.09
Rectum V75 (cc) 0.63 0.61 0.82 0.25 Rectum V75 (cc) 2.25 1.67 2.01 1.47
Urethra V100 (cc) 0.56 0.56 0.58 0.58 Urethra V100 (cc) 0.93 0.97 0.94 0.96
Urethra V120 (cc) 0.11 0.03 0.13 0.17 Urethra V120 (cc) 0.06 0.06 0.24 0.09
Target V100 (%) 95.4 94.2 96.6 92.1 Target V100 (%) 91.4 91.0 90.0 91.4
Target V150 (%) 35.2 32.8 36.1 32.8 Target V150 (%) 34.2 34.9 37.1 31.5
Target HI 0.63 0.65 0.63 0.64 Target HI 0.63 0.62 0.59 0.66
Case 4 (V=80.2cc) Original Cone Cone2 Firework Case 9 (V=89.0cc) Original Cone Cone2 Firework
Bladder V75 (cc) 0.78 0.84 0.86 0.90 Bladder V75 (cc) 5.08 4.40 4.40 3.24
Rectum V75 (cc) 0.35 0.76 0.87 0.48 Rectum V75 (cc) 1.53 1.73 1.36 1.61
Urethra V100 (cc) 1.76 1.80 1.71 1.75 Urethra V100 (cc) 1.54 1.52 1.53 1.55
Urethra V120 (cc) 0.05 0.22 0.48 0.14 Urethra V120 (cc) 0.14 0.01 0.11 0.11
Target V100 (%) 90.9 92.7 90.2 90.3 Target V100 (%) 92.2 91.1 90.0 90.6
Target V150 (%) 27.6 33.5 34.4 27.4 Target V150 (%) 30.7 28.8 33.0 34.9
Target HI 0.70 0.64 0.62 0.70 Target HI 0.67 0.68 0.63 0.62
Case 5 (V=43.4cc) Original Cone Cone2 Firework Case 10 (V=57.8cc) Original Cone Cone2 Firework
Bladder V75 (cc) 0.38 0.50 0.66 0.29 Bladder V75 (cc) 0.51 0.65 0.54 0.73
Rectum V75 (cc) 0.34 0.23 0.28 0.16 Rectum V75 (cc) 1.94 0.56 0.61 0.60
Urethra V100 (cc) 1.10 1.11 1.11 1.06 Urethra V100 (cc) 1.35 1.67 1.54 1.50
Urethra V120 (cc) 0.14 0.11 0.18 0.13 Urethra V120 (cc) 0.00 0.06 0.19 0.17
Target V100 (%) 96.8 95.6 95.9 94.1 Target V100 (%) 90.5 94.3 90.2 90.8
Target V150 (%) 43.0 35.7 36.3 38.7 Target V150 (%) 31.2 28.7 31.7 31.4
Target HI 0.56 0.63 0.62 0.59 Target HI 0.66 0.65 0.65 0.65
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Figure 4: Box-and-whisker plots of the data presented in Table 1 for prostate. HI is the prostate dose homogeneity index. A standard
median-value box-and-whisker construction is used: the box encompasses the inner two quartiles (the range of which is the inner
quartile range, IQR) with a hash at the median value of the distribution; the whiskers end at the lowest(highest) measured value within
the box edge minus(plus) 1.5× IQR. If there is no value within this range the whisker is not drawn (i.e. the whisker ends at the edge of
the box). The key element to note here is similarity of all results. The RTOG-0321 recommendation of 90% for the V Prostate100 and our
clinic’s recommendation of the prostate HI> 0.6 are indicated by the dashed horizontal line. Friedman’s Statistics, S, which compare
the set of four studies (control, conical, bi-conical, and fireworks) are S(V Prostate100 ) = 2.19 and S(HI) = 3.18. These values are both less
than the cutoff of 7.81 for an alpha of 0.05. We are therefore at least 95% confident that any differences in the plans is due purely to
random statistical fluctuations.
9
Figure 5: Box-and-whisker plots of the data presented in Table 1 for the organs at risk. The box and whisker generation is the same
as for Figure 4. (The lack of whiskers on some of the plots is directly related to the smallness of the box, i.e. it is a result of the
increase in consistency of that dosimetric variable across all patients.) As in Figure 4, the critical point here is to note the similarity
of the alternative patterns with respect to the Original. This is critical given that the alternative patterns are just as good as the
Original, parallel-catheter plans and they provide for avoidance of the contoured bulb/CSNB or pubic arch. (Note, there is a change
of scale versus the urethra plot for those of the bladder and rectum.) Our clinical requirement of V Urethra120 < 1.0 cc is indicated by the
limit of the ordinate in the Urethra plot. The RTOG-0321 recommended limit of V75 < 1.0 cc is indicated as the dashed horizontal
line for the latter two. Friedman’s statistics, S, which compare the set of four studies (control, conical, bi-conical, and fireworks) are
S(V Urethra120 ) = 3.63, S(V
Rectum
75 ) = 5.88, S(V
Bladder
75 ) = 2.97. These values are all less than the cutoff of 7.81 for an alpha of 0.05. We
are therefore at least 95% confident that any differences in the plans is due purely to random statistical fluctuations.
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